Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

221/435 Matches for
“Fatty Liver Disease”

“Fatty Liver Disease” Clear all
  1. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 100

    FibroTest SteatoTest Metabolic

  2. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 100

    …and quantification in nonalcoholic fatty liver disease (NAFLD). ### Methods Cross-sectional study…

    SteatoTest Metabolic

  3. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 100

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  4. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 100

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  5. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 100

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  6. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 99

    …FIB-4), non-alcoholic fatty liver disease fibrosis score (NFS), body mass…

    FibroTest Metabolic

  7. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 99

    …of liver disease, such as non-alcoholic fatty liver disease, hazardous alcohol…

    FibroTest Other

  8. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 99

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  9. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 99

    …characterize patients with nonalcoholic fatty liver disease (NAFLD). A multicenter study was…

    ActiTest FibroTest NashTest SteatoTest +1

  10. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 98

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  11. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 98

    …of non-alcoholic fatty liver disease (NAFLD). Since liver biopsy is invasive…

    FibroTest Metabolic

  12. Noninvasive evaluation of NAFLD. Review

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 98

    …developing complications of end-stage liver disease. Although it lacks sensitivity, ultrasonography…

    ActiTest FibroTest NashTest SteatoTest +1

  13. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 98

    …spectroscopy), fatty liver index score, non-alcoholic fatty liver disease fibrosis score…

    FibroTest NashTest Metabolic

  14. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 98

    …marianum on non alcoholic fatty liver disease (NAFLD). ### Methods In 72 patients…

    SteatoTest Metabolic

  15. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 97

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  16. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 97

    …Given that early identification of non-alcoholic fatty liver disease (NAFLD) is…

    NashTest SteatoTest Metabolic

  17. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 97

    Fatty liver was diagnosed with abdominal ultrasound and liver steatosis was quantified…

    FibroTest SteatoTest Metabolic

  18. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Match 97

    The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…

    FibroTest NashTest SteatoTest Metabolic

  19. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 96

    …CAP was significantly correlated with SteatoTest, Fatty Liver Index (FLI), percentage of…

    SteatoTest Metabolic

  20. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Match 96

    FibroTest Metabolic

  21. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 96

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  22. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

    Bril F et al. · J Investig Med · 2019 Match 96

    …the disease in those patients with non-alcoholic fatty liver disease (NAFLD…

    ActiTest FibroTest NashTest SteatoTest +1

  23. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 96

    …high risk of nonalcoholic fatty liver disease. Noninvasive tests of steatosis, nonalcoholic…

    FibroTest NashTest SteatoTest HIV

  24. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 95

    …In multivariate analysis, the predictive variables for advanced liver fibrosis were age…

    FibroTest Metabolic

  25. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 95

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  26. Noninvasive Assessment of Liver Fibrosis. Key publication Review

    Castera L et al. · N Engl J Med · 2025 Match 95

    FibroTest Metabolic

  27. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

    Bril F et al. · Diabetes Care · 2020 Match 95

    …nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However…

    FibroTest NashTest-2 Metabolic

  28. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 94

    …contributing factor for nonalcoholic fatty liver disease (NAFLD). NAFLD severity and its…

    FibroTest NashTest SteatoTest Metabolic

  29. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 94

    …We reviewed the landmark studies in metabolic liver disease, sources of the…

    ActiTest FibroTest NashTest NashTest-2 +3

  30. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 94

    FibroTest Metabolic

  31. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 94

    ActiTest AshTest FibroTest NashTest +6

  32. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 93

    …ELF, ≥10.43; Nonalcoholic Fatty Liver Disease Fibrosis Score, ≥1.80; Fibrotest…

    FibroTest Metabolic

  33. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 93

    …of liver morbidity and mortality in non-alcoholic fatty liver disease (NAFLD…

    FibroTest Metabolic

  34. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Match 93

    ### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease

    SteatoTest Metabolic

  35. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 93

    …hand and non-alcoholic fatty liver disease (NAFLD) on the other hand…

    ActiTest FibroTest NashTest SteatoTest +1

  36. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 93

    Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the…

    ActiTest FibroTest NashTest-2 Metabolic

  37. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 92

    …FIB4, BARD, and nonalcoholic fatty liver disease scores. A combination of NIT…

    FibroTest NashTest SteatoTest Metabolic

  38. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 92

    fatty liver disease with liver biopsy, blood fibrosis tests (Nonalcoholic Fatty Liver

    FibroTest Metabolic

  39. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 92

    …factor for non-alcoholic fatty liver disease (NAFLD) occurrence and progression. The…

    NashTest SteatoTest Metabolic

  40. FibroMAX: towards a new universal biomarker of liver disease? Review

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 92

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  41. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study. Key publication

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 91

    liver disease (MASLD) are linked to the development of peripheral artery disease

    ActiTest FibroTest NashTest SteatoTest +1

  42. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Review

    Brener S · Ont Health Technol Assess Ser · 2015 Match 91

    …B virus, nonalcoholic fatty liver disease, alcoholic liver disease, or cholestatic diseases…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  43. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Match 91

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…

    Metabolic

  44. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 91

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  45. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 91

    …nonalcoholic fatty liver disease leading to advanced fibrosis, cirrhosis, and liver cancer…

    FibroTest SteatoTest Metabolic

  46. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 90

    …standard for assessing nonalcoholic fatty liver disease (NAFLD) histologic lesions in patients…

    FibroTest NashTest SteatoTest Metabolic

  47. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 90

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease

    FibroTest Metabolic

  48. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 90

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  49. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 90

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  50. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 89

    …for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions. The aim…

    FibroTest Metabolic

  51. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 89

    …CHB and its consequences on liver injury compared with CHC and NAFLD…

    FibroTest SteatoTest HBV HCV +1

  52. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 89

    FibroTest Metabolic

  53. Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

    Caussy C et al. · Diabetes Care · 2025 Match 89

    …from metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in diabetology…

    FibroTest Metabolic

  54. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 89

    …Children present severe fatty liver disease with early cirrhosis. Before enzyme replacement…

    FibroTest Metabolic

  55. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.

    Ivancovsky-Wajcman D et al. · Dig Liver Dis · 2019 Match 88

    …protective potential in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), there…

    FibroTest NashTest SteatoTest Metabolic

  56. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis

    Poynard T et al. · PLoS One · 2012 Match 88

    …for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions in patients…

    ActiTest FibroTest NashTest SteatoTest +1

  57. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

    Gudowska M et al. · Adv Clin Exp Med · 2015 Match 88

    …This may indicate the presence of non-alcoholic liver disease in alcoholics.

    ActiTest AshTest FibroTest NashTest +2

  58. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 88

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  59. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 87

    …lesions of non-alcoholic fatty liver disease (NAFLD). The aim was to…

    NashTest Metabolic

  60. Glycogenic hepatopathy. Review

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Match 87

    …GH or for differentiation of this situation from nonalcoholic fatty liver disease.

    FibroTest Metabolic

  61. The non-invasive assessment of hepatic fibrosis. Review

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 87

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  62. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013 Match 87

    FibroTest Metabolic

  63. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 86

    …B, alcoholic liver disease, and non-alcoholic fatty liver disease, and were…

    SteatoTest Alcohol HBV HCV +1

  64. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 86

    …fibrosis in non-alcoholic fatty liver disease (NAFLD) with results similar to…

    FibroTest Alcohol HBV HCV +1

  65. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 86

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  66. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Review

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 86

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  67. Liver fibrosis markers in alcoholic liver disease. Review

    Chrostek L et al. · World J Gastroenterol · 2014 Match 86

    …The assessment of the degree of liver fibrosis in alcoholic liver disease

    FibroTest Alcohol

  68. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 85

    liver injury are less well validated in non-alcoholic fatty liver disease

    ActiTest FibroTest SteatoTest Metabolic

  69. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 85

    liver disease (59.6%) and chronic hepatitis B (52.9%). Liver biopsy…

    FibroTest Alcohol HBV HCV +3

  70. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Key publication

    Thiele M et al. · Gastroenterology · 2018 Match 85

    liver-related mortality, but we lack serum markers to detect compensated disease

    FibroTest Alcohol

  71. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 85

    FibroTest Alcohol HBV HCV +3

  72. Non-invasive markers for hepatic fibrosis. Review

    Baranova A et al. · BMC Gastroenterol · 2011 Match 84

    liver fibrosis is a vital need for successful individualized management of disease

    FibroTest Alcohol HBV HCV +3

  73. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. Review

    Lombardi R et al. · World J Gastroenterol · 2015 Match 84

    Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…

    FibroTest Alcohol

  74. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007 Match 84

    …assess the prevalence of advanced liver disease in a large population of…

    FibroTest NashTest SteatoTest Metabolic

  75. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.

    Mahamid M et al. · Clin Pharmacol · 2011 Match 84

    ### Background Elevation of liver enzymes in rheumatoid arthritis patients treated with tocilizumab…

    FibroTest Other

  76. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 84

    liver disease, hepatitis C, hepatitis B, and alcoholic or non alcoholic fatty

    FibroTest Alcohol HBV HCV +3

  77. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 83

    …both alcoholic and nonalcoholic fatty liver disease (NAFLD) in 66%, NAFLD in…

    FibroTest Alcohol HBV HCV +3

  78. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 83

    …between heart disease and metabolic-dysfunction-associated steatotic liver disease (MASLD); however…

    FibroTest Metabolic

  79. Biomarkers of liver fibrosis. Review

    Poynard T et al. · Adv Clin Chem · 2008 Match 83

    …C virus (HCV), hepatitis B virus (HBV), hepatitis nonalcoholic fatty liver disease

    ActiTest FibroTest SteatoTest Alcohol +5

  80. Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Meta Analysis

    Kovalic AJ et al. · Eur J Gastroenterol Hepatol · 2023 Match 83

    fatty liver disease (NAFLD). Due to well-documented flaws associated with liver

    FibroTest Metabolic

  81. Noninvasive diagnosis in alcohol-related liver disease.

    Hadefi A et al. · Health Sci Rep · 2020 Match 82

    liver diseases such as viral hepatitis and nonalcoholic fatty liver disease (NAFLD…

    FibroTest Alcohol

  82. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication

    Deckmyn O et al. · Biomedicines · 2022 Match 82

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  83. An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

    Poynard T et al. · Biomedicines · 2025 Match 82

    **Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  84. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 82

    …the prediction of non-alcoholic liver disease by non-invasive blood tests…

    FibroTest NashTest-2 SteatoTest Metabolic

  85. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 81

    …for the diagnostic of metabolic liver disease in patients with type-2…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  86. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 81

    liver fibrosis. ### Material And Methods 68 children with chronic liver disease requiring…

    FibroTest

  87. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 81

    …All patients in the cohort except 1 were managed without a liver

    FibroTest NashTest Other

  88. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 81

    …tests in patients with metabolic liver disease (MASLD). An unmet need is…

    FibroTest-T2D Metabolic

  89. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 81

    …evaluated for the assessment of liver fibrosis predominantly in patients with viral…

    FibroTest SteatoTest Other

  90. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 80

    fatty liver disease (NAFLD), and 218 with alcoholic fatty liver disease (ALD…

    FibroTest Alcohol HBV HCV +1

  91. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 80

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  92. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Key publication

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 80

    …chronic liver disease (CLD) such as autoimmune hepatitis, alcoholic liver disease and…

    ActiTest FibroTest Alcohol HBV +3

  93. Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Review

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 80

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  94. Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals.

    Istaces N et al. · Clin Biochem · 2015 Match 79

    …F3 liver fibrosis stages in non-alcoholic fatty liver disease with 34…

    FibroTest HBV HCV

  95. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Review

    Golabi P et al. · Expert Rev Gastroenterol Hepatol · 2016 Match 79

    Nonalcoholic steatohepatitis (NASH) can lead to complications such as liver failure, cirrhosis…

    FibroTest Metabolic

  96. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 79

    …The best marker of liver fibrosis in alcoholic patients seems to be…

    FibroTest Alcohol

  97. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 79

    …of metabolic dysfunction associated steatotic liver disease - namely fibrosis, metabolic dysfunction-associated…

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  98. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.

    Canivet CM et al. · Hepatology · 2023 Match 79

    …this algorithm in nonalcoholic fatty liver disease (NAFLD). ### Approach And Results One…

    FibroTest Metabolic

  99. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

    Boursier J et al. · J Hepatol · 2016 Match 78

    liver-related prognosis in patients with non-alcoholic fatty liver disease (NAFLD…

    FibroTest Metabolic

  100. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 78

    FibroTest Alcohol

  101. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 78

    …Investigations included assessment of abdominal ultrasonography, liver biopsy, calculation of body mass…

    HCV

  102. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study. Key publication

    Codjia T et al. · Obes Surg · 2021 Match 78

    …options for non-alcoholic fatty liver disease (NAFLD), affecting 90% of patients…

    FibroTest NashTest SteatoTest Metabolic

  103. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 77

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  104. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

    Rinella ME et al. · J Hepatol · 2022 Match 77

    …Non-alcoholic steatohepatitis (NASH) is a chronic, progressive liver disease that can…

    FibroTest Metabolic

  105. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 77

    …influenced by aetiology of chronic liver disease (CLD) and the stages of…

    FibroTest HBV HCV HIV +1

  106. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 77

    ### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…

    FibroTest Alcohol

  107. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 77

    …alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). The…

    FibroTest Alcohol HBV HCV +2

  108. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 76

    …of liver affection, and analyse the influence of the HIV disease severity…

    FibroTest HIV

  109. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 76

    …A total of 321 consecutive patients with chronic liver disease who underwent…

    FibroTest Alcohol HBV HCV +2

  110. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 76

    …patients with chronic liver disease or normal liver tissue that surrounded tumors…

    FibroTest Alcohol HBV HCV +3

  111. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 76

    …Patients with other risk factors for liver disease should be closely monitored…

    FibroTest Other

  112. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 75

    …transferrin (CDT%), is confounded by liver disease severity. The aim was to…

    FibroTest SteatoTest Alcohol

  113. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 75

    …Steatosis was demonstrated in all 5 patients who received liver biopsies during…

    FibroTest Other

  114. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 75

    …competitor as a biomarker of liver fibrosis in comparison with the standard…

    ActiTest FibroTest SteatoTest Alcohol +3

  115. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 75

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  116. The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.

    Gruszewska E et al. · Clin Lab · 2015 Match 74

    ### Background The aim of this study was to evaluate the prevalence of…

    AshTest NashTest Alcohol

  117. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Match 74

    …Further studies are needed to guide strategies for surveillance of liver disease

    FibroTest Other

  118. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 74

    …elderly patients without liver disease (group A, 85.2+/-7.3 years…

    FibroTest Metabolic

  119. Meta-analyses of FibroTest diagnostic value in chronic liver disease. Key publication Meta Analysis

    Poynard T et al. · BMC Gastroenterol · 2007 Match 74

    …chronic hepatitis B (CHB), alcoholic liver disease (ALD) and non-alcoholic fatty

    FibroTest Alcohol HBV HCV +1

  120. Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 74

    FibroTest HBV

  121. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 73

    …of non-invasive biomarkers in liver fibrosis. A scoring system has been…

    ActiTest FibroTest SteatoTest Alcohol +5

  122. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.

    Terrier B et al. · J Hepatol · 2011 Match 73

    …Serum levels of 25(OH)D3 were also significantly correlated with liver

    ActiTest FibroTest HCV HIV

  123. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 73

    ActiTest FibroTest Alcohol HBV +3

  124. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 73

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  125. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 72

    …male gender, older age, and NAFLD as a cause of liver disease

    FibroTest Alcohol HBV HCV +3

  126. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 72

    …AshTest is an appropriate non-invasive alternative to transjugular liver biopsy.

    AshTest Alcohol

  127. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.

    Ducancelle A et al. · J Clin Gastroenterol · 2017 Match 72

    …CHC) and non-alcoholic fatty liver disease (NAFLD). Therefore, we compared the…

    FibroTest Alcohol HBV HCV +2

  128. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 72

    …fibrosis and cirrhosis in chronic liver disease. However, there is no clear…

    FibroTest Alcohol

  129. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Match 72

    FibroTest Other

  130. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.

    Berends MA et al. · Liver Int · 2007 Match 71

    …To monitor this serial liver biopsies were performed. The Fibroscan and the…

    FibroTest Other

  131. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

    Sebagh M et al. · J Hepatol · 2012 Match 71

    ### Background & Aims Most liver transplant centres have discontinued the practice of protocol…

    ActiTest FibroTest Alcohol HBV +4

  132. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 71

    Liver biopsy, because of its limitations and risks, might be considered an…

    ActiTest FibroTest HCV

  133. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. Key publication

    Peta V et al. · Clin Res Hepatol Gastroenterol · 2020 Match 71

    …HCC in patients with chronic liver disease including those without cirrhosis. Its…

    ActiTest FibroTest Alcohol HBV +2

  134. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 70

    …To evaluate the association between anthropometric measurements and advanced liver disease in…

    ActiTest FibroTest HCV

  135. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 70

    …Conclusions In patients with chronic liver disease the LCR1 and LCR2 tests…

    LCR1 LCR2 Alcohol HBV +4

  136. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Match 70

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver

    FibroTest HCV

  137. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

    Sadler MD et al. · Can J Gastroenterol Hepatol · 2015 Match 70

    ### Background Liver disease is the third leading cause of mortality in patients…

    FibroTest Other

  138. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

    Dezanet LNC et al. · Liver Int · 2021 Match 70

    ### Background & Aims Data on liver fibrosis evolution and its involvement in liver

    FibroTest HBV HIV

  139. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.

    Knop V et al. · Nutrition · 2019 Match 69

    …risk for intestinal failure-associated liver disease (IFALD). The aim of the…

    FibroTest SteatoTest Other

  140. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 69

    …SVR benefits are well-recognized with reductions in rates of liver complications…

    FibroTest HCV

  141. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.

    Vermehren J et al. · Liver Int · 2012 Match 69

    …54 ± 11 years) with chronic liver disease and established cirrhosis were included…

    FibroTest Alcohol HBV HCV +3

  142. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 69

    …assess liver fibrosis is insufficiently validated in alcoholic liver disease (ALD). We…

    FibroTest Alcohol

  143. Acoustic Radiation Force Impulse Imaging for Diagnosis and Monitoring of Liver Fibrosis in Patients with Hepatitis C: A Review of Diagnostic Accuracy, Clinical Effectiveness, Cost-Effectiveness, and Guidelines Review

    · 2016 Match 68

    …This also allows for a sonographic evaluation of the liver to be…

    FibroTest HCV

  144. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Match 68

    …in order to avoid the liver biopsy currently used for selection of…

    FibroTest HCV

  145. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.

    Adler M et al. · Hepatology · 2008 Match 68

    FibroTest Alcohol HBV HCV +1

  146. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Match 68

    …patients with chronic liver disease, who received a liver biopsy, transient elastography…

    FibroTest HBV HCV Other

  147. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 67

    FibroTest Other

  148. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 67

    ActiTest AshTest FibroTest NashTest +7

  149. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 67

    ActiTest FibroTest HCV

  150. [Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Review

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 67

    …depending on etiology and disease stage. Liver biopsy, traditionally regarded as the…

    FibroTest HCV

  151. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 67

    ActiTest FibroTest HBV

  152. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010 Match 66

    FibroTest Alcohol HBV HCV +1

  153. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2023 Match 66

    FibroTest Metabolic

  154. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 66

    Liver disease in UCDs may be associated with hepatic inflammation, hepatic fibrosis…

    ActiTest FibroTest Other

  155. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 66

    liver disease severity. ### Objective To compare the awareness of liver disease severity…

    ActiTest FibroTest Alcohol HBV +3

  156. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. Key publication

    Thabut D et al. · J Hepatol · 2006 Match 65

    …in patients with chronic alcoholic liver disease. ### Methods Biomarkers were assessed in…

    AshTest Alcohol

  157. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 65

    …development of alcohol-related liver disease (ALD). Liver biopsy may be used…

    FibroTest Alcohol

  158. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 65

    …various aspects of liver fibrosis relevant to disease patterns and clinical practice…

    FibroTest SteatoTest HBV HCV +1

  159. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 65

    ### Background Systematic screening for liver fibrosis in heavy-drinking patients is a…

    FibroTest Alcohol

  160. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 65

    …and ninety patients with chronic liver disease of miscellaneous causes were included…

    FibroTest Alcohol HBV HCV +2

  161. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.

    Sturm N et al. · Liver Int · 2013 Match 64

    ### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…

    FibroTest HBV HCV

  162. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 64

    …serum-based assessment of liver fibrosis is still an important diagnostic challenge…

    ActiTest FibroTest HCV

  163. [Prognosis assessment of alcoholic liver disease: how and why?]. Review

    Trabut JB et al. · Presse Med · 2014 Match 64

    Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…

    FibroTest Alcohol

  164. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.

    Morra R et al. · Aliment Pharmacol Ther · 2007 Match 64

    ### Background FibroTest has been validated for the diagnosis of liver fibrosis in…

    FibroTest Alcohol HBV HCV +1

  165. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011 Match 63

    FibroTest HCV

  166. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 63

    …the early spread of coronavirus disease 2019 (Covid-19) in the general…

    FibroTest Other

  167. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 63

    …infection or non-HCV-related liver diseases. ### Methods And Results The optimal…

    FibroTest Alcohol HBV HCV +2

  168. American Association for the Study of the Liver

    Match 63

    FibroTest HCV

  169. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.

    Crisan D et al. · Indian J Med Res · 2017 Match 62

    …Histological features were assessed invasively by liver biopsy and noninvasively using FibroTest…

    ActiTest FibroTest SteatoTest HCV

  170. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 62

    …The impact of treatment with ADV vs placebo was assessed on liver

    ActiTest FibroTest HBV

  171. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Review

    Parikh P et al. · Ann Transl Med · 2017 Match 62

    …The reliance on invasive liver biopsy to stage disease is diminishing with…

    FibroTest HBV

  172. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 62

    ### Background And Aims Liver stiffness measurement (LSM) and FibroTest (FT) are frequently…

    FibroTest HBV

  173. Non-invasive diagnosis of hepatitis B virus-related cirrhosis. Review

    Lee S et al. · World J Gastroenterol · 2014 Match 62

    Liver biopsy is the reference standard for assessment of liver fibrosis. However…

    FibroTest HBV

  174. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Match 61

    Fontan-associated liver disease (FALD) is a serious complication related to the…

    FibroTest Other

  175. Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.

    Kucharska M et al. · Pol Arch Intern Med · 2017 Match 61

    …chronic liver disease in patients with hemophilia. However, since liver biopsy should…

    FibroTest HCV

  176. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review

    Ahmad W et al. · Virol J · 2011 Match 61

    disease from initial to end stage (mild fibrosis to cirrhosis). Although, liver

    FibroTest HCV

  177. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 61

    …chronic liver diseases and whether those levels correlate with disease severity. We…

    FibroTest HCV

  178. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 60

    …these findings in women and in people with other chronic liver diseases.

    FibroTest HCV

  179. [The prevalence of liver and gallbladder pathologies in overweight and obese patients].

    Popova IR et al. · Klin Med (Mosk) · 2012 Match 60

    …Nonalcoholic fatty liver disease was diagnosed using hepatic elastography and senrum markers…

    ActiTest FibroTest NashTest SteatoTest +1

  180. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 60

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver

    FibroTest Other

  181. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

    Leroy V et al. · J Hepatol · 2007 Match 60

    ### Background/Aims Non-invasive markers of liver fibrosis have recently been developed…

    FibroTest HCV

  182. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Key publication

    Poynard T et al. · Clin Chem · 2004 Match 60

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  183. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 59

    …fibrosis in patients with chronic liver disease. This paper aims to assess…

    FibroTest Alcohol HBV HCV +3

  184. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Match 59

    …evaluation of liver fibrosis in patients with Crohn's disease. ### Methods A…

    FibroTest Other

  185. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Review

    Castera L · J Viral Hepat · 2009 Match 59

    The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…

    FibroTest HBV HCV HIV

  186. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 59

    FibroTest Other

  187. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 58

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  188. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Match 58

    …clinical evidence of end-stage liver disease. Predictive values of blood markers…

    FibroTest

  189. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.

    Corradi F et al. · Dig Liver Dis · 2009 Match 58

    ### Background Progression of recurrent hepatitis C is accelerated in liver transplant recipients…

    FibroTest HCV

  190. Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.

    Friedrich-Rust M et al. · Ultraschall Med · 2009 Match 58

    …with chronic liver disease and either histological assessment of liver fibrosis (n…

    FibroTest Alcohol HBV HCV +2

  191. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Match 58

    …a Model for End-Stage Liver Disease score ≥ 10 (24% [14-37…

    FibroTest HCV

  192. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.

    Friedrich-Rust M et al. · J Cyst Fibros · 2013 Match 57

    …mortality caused by CF-related liver-disease. While transient elastography (TE) is…

    FibroTest Other

  193. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 57

    …These consisted of 29 healthy volunteers and 35 patients with chronic liver

    ActiTest FibroTest Alcohol HBV +3

  194. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Match 57

    ### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…

    ActiTest FibroTest HCV

  195. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 57

    ### Background Liver stiffness and non-invasive tests predict overall survival in chronic…

    FibroTest HBV

  196. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

    Crisan D et al. · Hepat Mon · 2012 Match 56

    …management of patients with chronic liver disease. Non-invasive tests (NITs) have…

    FibroTest HCV

  197. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 56

    …compared with FibroTest (FT) and liver stiffness measurement (LSM) by transient elastography…

    FibroTest Alcohol HBV HCV +3

  198. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

    Colletta C et al. · Hepatology · 2005 Match 56

    …We aimed to verify whether monitoring by liver biopsy might be replaced…

    FibroTest HCV

  199. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection

    · 2015 Match 56

    …to assess the stage of liver disease and eligibility for treatment; prioritize…

    FibroTest HBV

  200. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

    Myers RP et al. · Dig Dis Sci · 2003 Match 55

    As an alternative to liver biopsy, an index of five biochemical markers…

    FibroTest HCV

  201. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 55

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  202. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. Review

    Stasi C et al. · World J Gastroenterol · 2016 Match 55

    …In this case, liver biopsy is still required to properly assess liver

    FibroTest HCV

  203. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Match 55

    ### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…

    FibroTest HCV HIV

  204. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference. Key publication

    Peta V et al. · World J Hepatol · 2025 Match 55

    ActiTest FibroTest Autoimmune hepatitis

  205. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Match 54

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  206. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Match 54

    ### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…

    FibroTest Other

  207. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 54

    …better biomarkers of drug-induced-liver-injury (DILI). ### Aims We aimed to…

    ActiTest FibroTest Other

  208. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 54

    …including hepatic necroinflammatory activity, on liver stiffness measurement (LSM). This prospective study…

    FibroTest HCV

  209. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 53

    …All patients had a liver biopsy. The Hepascore and FibroTest were calculated…

    FibroTest Other

  210. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

    Poynard T et al. · J Hepatol · 2011 Match 53

    ### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…

    FibroTest HCV

  211. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 53

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  212. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication

    Poynard T et al. · JHEP Rep · 2021 Match 53

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  213. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 53

    ### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…

    FibroTest HCV HIV

  214. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 52

    ActiTest FibroTest HBV

  215. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.

    Gangadharan B et al. · PLoS One · 2012 Match 52

    ### Background Liver biopsy is the reference standard for assessing liver fibrosis and…

    FibroTest HCV

  216. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 52

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  217. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Key publication

    Poynard T et al. · Gastro Hep Adv · 2022 Match 52

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 HBV

  218. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.

    Mbaye PS et al. · PLoS One · 2011 Match 51

    …We sought to evaluate liver stiffness measurement by FibroScan® (LSM) and two…

    FibroTest HBV

  219. Reproducibility of blood tests of liver fibrosis in clinical practice.

    Calès P et al. · Clin Biochem · 2008 Match 51

    ### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver

    FibroTest Alcohol HBV HCV +1

  220. [Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].

    Piton A et al. · Ann Biol Clin (Paris) · 2005 Match 51

    ### Background Alpha2Macroglobulin (A2M) measure showed a revival since it was introduced into…

    ActiTest FibroTest

  221. Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.